Kisspeptin

Kisspeptin is a neuropeptide encoded by the KISS1 gene, central to reproductive hormone regulation through stimulation of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. It is the master regulator of puberty onset and reproductive endocrine function in humans. Synthetic kisspeptin analogs (including kisspeptin-10, kisspeptin-54) are researched for fertility treatment, induction of ovulation, and as diagnostic agents for hypothalamic-pituitary axis function. Kisspeptin is not approved for routine therapeutic use but has been used clinically in research and specialty fertility contexts.

What is Kisspeptin and how does the reproductive endocrine mechanism work?

Kisspeptin is the active product of the KISS1 gene, secreted by neurons in the hypothalamic arcuate nucleus and anteroventral periventricular nucleus, that directly stimulates GnRH neuron firing through binding to the KISS1 receptor (GPR54). This GnRH stimulation drives downstream LH and FSH release from the pituitary and subsequent gonadal steroid production. Kisspeptin is the proximal upstream regulator of the entire reproductive endocrine axis — KISS1 loss-of-function mutations produce hypogonadotropic hypogonadism and failure of puberty. Several active fragments exist (kisspeptin-10, kisspeptin-54), differing by length but sharing the C-terminal active region.

Evidence level: established reproductive biology; Phase 1/2 human clinical research; fertility specialty use in research contexts

What does the research show for Kisspeptin?

Phase 1/2 clinical research has explored kisspeptin for ovulation induction in subfertile women, as a diagnostic agent for hypogonadotropic hypogonadism, and as a more physiological approach to assisted reproduction than conventional GnRH-based protocols. The most rigorous human data come from Imperial College London's programme led by Waljit Dhillo. Example: a randomized, double-masked, placebo-controlled crossover trial published in JAMA Network Open (2022) infused kisspeptin-54 intravenously in premenopausal women with hypoactive sexual desire disorder (40 randomized; 32 completed both arms) and found modulation of sexual-brain processing on functional MRI, with related trials in men reported by the same group. These are supervised, proof-of-mechanism infusion studies — not efficacy trials, and not evidence about self-administered research-grade material. The fertility application is particularly mechanistically interesting because kisspeptin-induced ovulation appears to carry lower ovarian hyperstimulation syndrome (OHSS) risk than human chorionic gonadotropin (hCG) triggers. Phase 3 development for fertility indications is in earlier stages than for many other peptides.

Source: Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial, Thurston L. … Dhillo W.S. (corresponding), JAMA Network Open, 2022 · Evidence level: phase 1/2 (fertility, diagnostic); established reproductive biology; no Phase 3 approval

How does Kisspeptin compare to other reproductive endocrine compounds?

Kisspeptin acts at the proximal upstream point of the reproductive endocrine axis — distinct from GnRH analogs (which act at the pituitary GnRH receptor), gonadotropins (which act at gonadal receptors), and steroid hormones (which act directly on target tissues).

See the kisspeptin vs gonadorelin vs hCG comparison for mechanism-level differences.

What are the documented side effects of Kisspeptin?

Side effects in Phase 1/2 clinical research have been generally mild — injection-site reactions and occasional transient headache. The proximal upstream mechanism means kisspeptin produces physiological-pattern hormonal responses rather than the supra-physiological levels of conventional gonadotropin protocols, which underlies the proposed OHSS-risk reduction. Long-term safety at sustained dosing is not characterized at Western RCT standards.

Evidence level: phase 1/2 safety data; long-term unestablished

What is the regulatory status of Kisspeptin?

Kisspeptin is not approved for routine therapeutic use anywhere in the world as of August 2026. Two regulatory specifics matter here. First, kisspeptin-10 is on the FDA's active Category 2 list of bulk drug substances nominated for section 503A compounding — the category FDA flags as raising significant safety risks in compounding — one of only five peptides on that list (with GHRP-2, GHRP-6, ibutamoren, and ipamorelin acetate; verified August 2026). That listing restricts pharmacy compounding; it is separate from the research-chemical market this page tracks. Second, for tested athletes, the 2026 WADA Prohibited List names "kisspeptin and its agonist analogues" under S2.2.1 (testosterone-stimulating peptides) — prohibited at all times in males. Specialty fertility research use occurs at academic medical centers and in specific clinical trial contexts. Research-grade kisspeptin (kisspeptin-10 most commonly) is sold by third-party laboratories for laboratory use. Regulatory context in are peptides legal regulatory status by country.

Sources: FDA 503A bulk drug substances (Category 1/2) page; WADA Prohibited List (current year)

Why does Kisspeptin vendor verification matter?

Kisspeptin variants (kisspeptin-10 versus kisspeptin-54 versus full-length) have different properties and are not interchangeable, requiring clear labeling and mass spectrometry verification. Independent HPLC purity testing is the standard quality signal. The reproductive endocrine effects of kisspeptin mean buyers should be particularly careful about quality given the potency of the proximal-upstream mechanism. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Kisspeptin vendors?

Peptigrity collects independent third-party Certificates of Analysis for kisspeptin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Kisspeptin do?

Kisspeptin stimulates GnRH neurons in the hypothalamus, driving the entire reproductive endocrine axis through downstream LH/FSH release and gonadal steroid production. It is the master regulator of puberty onset and reproductive function; research interest focuses on fertility treatment and diagnostic applications.

Is Kisspeptin legal to purchase?

Kisspeptin is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for routine therapeutic human use. Country breakdown in peptide legal status guide.

Will Kisspeptin be FDA-approved?

Phase 1/2 research is ongoing for fertility and diagnostic indications, but Phase 3 development is in earlier stages than for many other peptide candidates. FDA approval is not imminent as of August 2026.

What's the difference between Kisspeptin-10 and Kisspeptin-54?

Both are active fragments of full-length kisspeptin sharing the C-terminal active region — Kisspeptin-10 is the shorter fragment (10 amino acids), Kisspeptin-54 is the longer form (54 amino acids). They have different pharmacokinetics with KP-10 being more commonly used in research-grade markets. Confirm which variant a vendor sells.

How can I verify a Kisspeptin vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation appropriate to the specific kisspeptin variant. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Kisspeptin dose?

No. Kisspeptin is not approved for routine therapeutic use and Peptigrity is an independent review platform, not a medical authority. Clinical research protocols vary by indication. Anyone considering use — particularly for fertility purposes — should consult a licensed physician about evidence-based reproductive endocrine options.

This section is for educational and informational purposes only and does not constitute medical advice. Kisspeptin is not approved by the FDA or any major Western regulator for routine therapeutic use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.